SEC Form 4 · accession 0000874015-18-000004
IONIS PHARMACEUTICALS INC · IONS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stanley T Crooke
Officer — Chairman and CEO · Director
Period of report
Jan 2, 2018
Accepted (ET)
Jan 2, 2018 · 8:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874015
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $49.25 | Jan 2, 2018 | A | 158,175 | A | Jan 2, 2019 | Jan 2, 2025 | Common Stock | 158,175 | 158,175 | D |
| Employee Stock Option (right to buy)F2 | $49.25 | Jan 2, 2018 | A | 17,603 | A | Jan 2, 2019 | Jan 1, 2025 | Common Stock | 17,603 | 17,603 | I |
Explanation of responses
- F1Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 39,544 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018.
- F2Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 4,401 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018.